Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
复制标题
DOI：
10.1182/blood-2012-05-431825
复制
发表时间：
2012-09-27
期刊：
影响因子：
20.3
通讯作者：
Salles, Gilles
中科院分区：
文献类型：
--
作者：
Ghesquieres, Herve;Cartron, Guillaume;Salles, Gilles
在接受单药利妥昔单抗治疗的滤泡性淋巴瘤患者中，FCGR3A基因的单核苷酸多态已知会影响疗效和无进展生存。FCGR3A和FCGR2A基因多态性在接受利妥昔单抗和化疗联合治疗的滤泡性淋巴瘤患者中的预后作用仍然存在争议，还没有在利妥昔单抗维持的背景下进行评估。在PRIMA研究中，分别对460例和455例接受治疗的患者进行了FCGR3A和FCGR2A单核苷酸多态性的评估，以探讨它们是否与利妥昔单抗化疗诱导和维持2年后的应答率和患者预后有关。在这个有代表性的患者队列中，FCGR3A VV、VF、FF和FCGR2AHH、HR、RR携带者的完全缓解率和未确认完全缓解率分别为65%、67%、66%(P=.86)和60%、72%、66%(P=0.21)。在利妥昔单抗维持(或观察)2年后，不同基因型别的应答率没有差异。从治疗开始或随机化到观察或维持，无进展存活率不受这些基因多态性的影响。这些数据表明，在联合化疗或用于维持治疗时，FCGR3A和FCGR2A基因多态性不影响缓解率和结果。PRIMA研究在www.Clinicaltrials.gov上注册为NCT00140582。(血。2012年；120(13)：2650-2657)
In patients with follicular lymphoma treated with single-agent rituximab, single nucleotide polymorphisms in the FCGR3A gene are known to influence response and progression-free survival. The prognostic role of FCGR3A and FCGR2A polymorphisms in patients with follicular lymphoma treated with rituximab and chemotherapy combination remains controversial and has not been evaluated in the context of rituximab maintenance. FCGR3A and FCGR2A single nucleotide polymorphisms were evaluated in, respectively, 460 and 455 patients treated in the PRIMA study to investigate whether these were associated with response rate and patient outcome after rituximab chemotherapy induction and 2-year rituximab maintenance. In this representative patient cohort, complete and unconfirmed complete responses after rituximab chemotherapy were observed in 65%, 67%, 66% (P = .86) and 60%, 72%, 66% (P = .21) of FCGR3A VV, VF, FF and FCGR2A HH, HR, RR carriers, respectively. After 2 years of rituximab maintenance (or observation), response rates did not differ among the different genotypes. Progression-free survival measured from either treatment initiation or randomization to observation or maintenance was not influenced by these polymorphisms. These data indicate that FCGR3A and FCGR2A polymorphisms do not influence response rate and outcome when rituximab is combined with chemotherapy or used as maintenance treatment. The PRIMA study is registered at www.clinicaltrials.gov as NCT00140582. (Blood. 2012; 120(13):2650-2657)